Select Page

The latest report on “Pompe Disease Treatment Market (Therapy Type – Enzyme Replacement Therapy, and Substrate Reduction Therapy; Molecule Type – Biologics, and Small Molecules; Route of Administration – Oral, and Parenteral; Dosage Forms – Solid, and Liquid): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025.” The global pompe disease treatment market is projected to grow at a CAGR of 9.0% over the forecast period of 2019-2025.

Ask for Sample Copy of Research Report with Table of Content @

Pompe disease is a rare neuromuscular disorder that occurs in children, infants, and adults who inherit a defective gene from their parents. It is one of the genetic diseases known as lysosomal storage disorders. The symptoms of Pompe disease are insufficient or missing amounts of an enzyme called acid alpha-glucosidase (GAA). This enzyme is needed to break down a complex sugar molecule into is a simple sugar that our bodies use for energy. Pompe disease is a progressive disease that gets worse over time. This disease causes progressive muscle weakness and often leads to breathing problems. It is also considered as a metabolic muscle disease. It is similar to other neuromuscular disorders such as muscular dystrophies.

The growing special regulatory drug designations for orphan drugs and increasing research activities performed to find an effective treatment for the disease are driving the pompe disease treatment market. Further Enzyme replacement therapies and growing developments in gene therapy also provide significant growth to the market. However, inflated costs associated with Pompe disease therapy is hindering the growth of the market. Moreover, emerging immunotherapeutic approaches for pompe disease provide growth opportunities for pompe disease treatment market.

North America is the Largest Region for Global Pompe Disease Treatment Market

Geographically, the pompe disease treatment market is segmented into North America, Europe, the Asia-Pacific, and the Row. North America is the largest region for global pompe disease treatment market. The occurrence of the disease is 1 out of 40,000 births in the U.S. drug and food administration has approved an enzyme replacement therapy Lumizyme® is used for patients older than 8 years of age. Whereas Myozyme® for the infantile-onset of Pompe disease suffering patients of less than 8 years old. Asia-Pacific is expected to grow with healthy CAGR owing to healthcare facilities and increasing awareness among patients regarding rare disorders.

Segment Covered

The report on global pompe disease treatment market covers segments such as therapy type, molecule type, route of administration, and dosage forms. On the basis of therapy type, the sub-markets include enzyme replacement therapy, and substrate reduction therapy. On the basis of molecule type, the sub-markets include biologics, and small molecules. On the basis of route of administration, the sub-markets include oral, and parenteral. On the basis of dosage forms, the sub-markets include solid, and liquid.

Browse Detailed TOC, Description, and Companies Mentioned in Report @

Companies Profiled:

The report provides profiles of the companies in the market such as BioMarin Pharmaceutical, Amicus Therapeutics, Genzyme company, Oxyrane, Audentes Therapeutics, Sangamo BioSciences, EpiVax, and Valerion Therapeutics.

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of the pompe disease treatment.

=> Complete coverage of all the product type and application segments to analyze the trends, developments, and forecast of market size up to 2025.

=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.  

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.